BTLA and systemic lupus erythematosus: As BTLAlow DN memory B cells are enriched in patients with active SLE and exhibit an antibody-secreting cell phenotype, belimumab possibly contributes to disease improvement by modulating the balance of BTLA-expressing memory B cells (Figure 3E).